Westminster, CO – According to filings with the U.S. Securities and Exchange Commission, Cerapedics is raising $24,999,997.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Glen Kashuba played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cerapedics
Cerapedics is an advanced orthobiologics company, enhancing the science of bone repair in orthopedic and spinal fusion procedures with i-FACTOR Peptide Enhanced Bone Graft. Among 400+ spinal bone grafts on the market, spine surgeons can feel confident in choosing i-FACTOR Peptide Enhanced Bone Graft which is backed by Level 1 human clinical data from an IDE study published in Spine and Neurosurgery. In this study i-FACTOR demonstrated high fusion rates and statistical superiority vs. autograft in overall clinical success. One of only two Class III FDA-PMA approved spinal bone grafts, i-FACTOR is the leading evidence-based alternative and is powered by a first of its kind molecule called P-15: Osteogenic Cell Binding Peptide. i-FACTOR is free of many safety risks seen with other products such as ectopic bone formation and on average costs at least 30% less expensive than other drug-device combination products.

To learn more about Cerapedics, visit http://www.cerapedics.com/

Contact:
Glen Kashuba, Chief Executive Officer
303-974-6281
gkashuba@cerapedics.com
https://www.linkedin.com/in/glen-a-kashuba-79b55438/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved